Precigen Inc (PGEN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.63B
Last updated: Nov 17, 2026 at 11:06 AM ET
Precigen Inc (PGEN) Stock Forecast
Analysts expect Precigen (PGEN) to earn $0.25 per share in the fiscal year ending Dec 31, 2026, on revenue of $241.76M. Of 4 analysts, 3 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 2 | 50.0% |
| Hold | 1 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 148.0% and revenue estimates rise 84.7%.
- Fiscal year ending Dec 31, 2026
- $0.25
- EPS consensus, revenue $241.76M
- Fiscal year ending Dec 31, 2027
- $0.62
- EPS consensus, revenue $446.43M
- Next report
- Mar 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.25 | $0.23 to $0.27 | 3 | $241.76M | $241.05M to $242.82M | 3 |
| Dec 31, 2027 | $0.62 | $0.43 to $0.95 | 4 | $446.43M | $385.20M to $523.34M | 4 |
Quarterly Estimates
The EPS consensus rises from $0.12 for the quarter ending Dec 31, 2026 to $0.15 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.12 | $0.11 to $0.14 | 6 | $89.64M | $81.44M to $94.97M | 6 |
| Mar 31, 2027 | $0.15 | $0.13 to $0.17 | 2 | $97.70M | $97.70M to $97.70M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 13.6% from $0.22.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.25 | $0.22 | $0.22 | $0.22 | $0.22 | +11.8% |
| Fiscal year ending Dec 31, 2027 | $0.62 | $0.62 | $0.63 | $0.68 | $0.68 | -9.5% |
| Quarter ending Mar 31, 2027 | $0.15 | $0.17 | $0.17 | $0.17 | $0.17 | -11.8% |
Frequently Asked Questions About PGEN
What is the PGEN stock forecast?
Consensus analyst estimates put Precigen's EPS at $0.25 for the fiscal year ending Dec 31, 2026, on revenue of $241.76M. The consensus rating from 4 analysts is Buy.
How do analysts rate PGEN stock?
Of 4 analysts covering Precigen, 1 rates it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PGEN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.25, with estimates from $0.23 to $0.27 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.62, with estimates from $0.43 to $0.95 from 4 analysts.
What revenue do analysts expect from Precigen next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $241.76M, with estimates from $241.05M to $242.82M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $446.43M, with estimates from $385.20M to $523.34M.
How many analysts cover PGEN?
4 analysts rate Precigen stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors